Arcturus Therapeutics Holdings Inc.
NASDAQShort sellers have built a deeply entrenched position in ARCT ahead of its Q1 2026 results tonight — and the borrow market tells a quietly unusual story for a stock trading at $8.90. Short interest runs at 21.6% of the free float, one of the most heavily shorted readings in the biotech universe. The ORTEX short score has climbed to 81.9, ranking in just the 2nd percentile across…
Snapshot as of 24 Jun 2026
Short sellers have built a deeply entrenched position in ARCT ahead of its Q1 2026 results tonight — and the borrow market tells a quietly unusual story for a stock trading at $8.90. Short interest runs at 21.6% of the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ARCT — free to start on ORTEX.
Sign up for free →Open ARCT on ORTEX